Accomplished healthcare and finance leader brings strategic experience and vision to Healthcare & Life Sciences Investment Banking Team NEW YORK, NY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- EF Hutton, an investment bank headquartered in New York, today announced the appointment of David Sans, PhD, FAARM MBA, as Managing Director, Head of Healthcare, to lead the Company’s Healthcare & Life Sciences Investment Banking Team.

2024年1月3日，纽约（环球通讯社）——通过NewMediaWire——总部位于纽约的投资银行EF Hutton，今天宣布任命FAARM MBA博士David Sans为董事总经理、医疗保健负责人，领导公司的医疗保健和生命科学投资银行团队。

David Sans, PhD, FAARM MBA, brings many years of biotech and pharma experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies.  Previously, David served as Head of Market Analytics at Pfizer during the launch of Rebif® (interferon beta-1a for MS) and Macugen® (pegaptanib) and as Sr.

FAARM MBA博士David Sans在大型制药公司和新兴生物技术公司的企业融资、业务发展、运营和商业角色方面拥有多年的生物技术和制药经验。此前，David在推出Rebif®（MS干扰素β-1a）和Macugen®（pegaptanib）期间担任辉瑞公司市场分析主管，并担任Sr。

Medical Scientist at Novartis in Basel, Switzerland during the launch of Glivec® (imatinib), at ImClone Systems and Head of Corporate Development and David served as an Executive Officer at Mount Sinai Health Systems completing Business Development transactions with Philips, LabCorp, and Agilent. David is also a Board Member of the Lymphatic Education & Research Network in New York.

瑞士巴塞尔诺华公司（Novartis）的医学科学家，在ImClone Systems推出Glivec®（伊马替尼）期间担任公司开发负责人，David担任西奈山健康系统（Mount Sinai Health Systems）的执行官，完成与飞利浦（Philips）、LabCorp和安捷伦（Agilent）的业务开发交易。David也是纽约淋巴教育与研究网络的董事会成员。

Dr. Sans holds a PhD in Chemical Engineering from University Ramon Lull in collaboration with the ETH in Zürich, an MBA in Business Law from Fordham in NYC, and he is the recipient of the Don Sheehan International Scholarship to the Wharton School of Business in Philadelphia. David holds a Fellowship in Anti-Aging and Regenerative Medicine (FAARM) from the American Academy and Board of Regenerative Medicine.

Sans博士拥有拉蒙·卢尔大学（University Ramon Lull）的化学工程博士学位，与苏黎世（Zürich）的ETH合作，拥有纽约州福德汉姆（Fordham）的商法MBA学位，他是费城沃顿商学院（Wharton School of Business）Don Sheehan国际奖学金的获得者。David拥有美国科学院和再生医学委员会的抗衰老和再生医学奖学金（FAARM）。

“We continue to see innovation and opportunity across the healthcare continuum in biotechnology, medical devices, healthcare IT, healthcare services, and therapeutics, and.

“我们继续在生物技术、医疗设备、医疗保健IT、医疗保健服务和治疗学等医疗保健领域看到创新和机遇。